|
Parameter
|
Cases (%)
|
SUVmax
|
SUVmean
|
MTV
|
TLG
|
|---|
|
Histopathological grade
|
|
G 1
|
15 (45.5%)
|
14.64 ± 4.26
|
7.39 ± 1.97
|
21.09 ± 9.57
|
166.97 ± 105.75
|
|
G 2&3
|
18 (54.5%)
|
19.19 ± 7.3
|
9.06 ± 3.34
|
37.53 ± 16.51
|
348.05 ± 222.83
|
|
P-value
| |
0.0414
|
0.0986
|
0.0019
|
0.0071
|
|
95% CI
| |
0.188 to 8.912
|
− 0.33 to 3.67
|
6.59 to 26.29
|
52.975 to 309.185
|
|
Myometrial invasion
|
|
< 50%
|
15 (45.5%)
|
12.75 ± 2.23
|
6.52 ± 1.71
|
19.95 ± 9.86
|
132.86 ± 84.91
|
|
> 50%
|
18 (54.5%)
|
20.77 ± 6.67
|
9.79 ± 2.89
|
38.49 ± 15.32
|
376.48 ± 202.22
|
|
P-value
| |
0.0001
|
0.0006
|
0.0003
|
0.0001
|
|
95% CI
| |
4.34 to 11.7
|
1.538 to 5.002
|
9.172 to 27.908
|
129.356 to 357.884
|
|
LVSI
|
|
Negative
|
15 (45.5%)
|
14.06 ± 4.28
|
6.65 ± 1.88
|
20.64 ± 8.94
|
139.63 ± 82.05
|
|
Positive
|
18 (54.5%)
|
19.68 ± 6.95
|
9.68 ± 2.92
|
37.91 ± 16.42
|
370.83 ± 209.69
|
|
P-value
| |
0.0104
|
0.0016
|
0.0010
|
0.0004
|
|
95% CI
| |
1.416 to 9.824
|
1.244 to 4.816
|
7.599 to 26.941
|
113.708 to 348.692
|
|
LNMs
|
|
Negative
|
24 (72.7%)
|
14.8 ± 4.33
|
7.22 ± 2.09
|
24.47 ± 12.37
|
176.26 ± 97.99
|
|
Positive
|
9 (27.3%)
|
23.32 ± 7.27
|
11.19 ± 2.87
|
44.98 ± 15.15
|
504.36 ± 209.42
|
|
P-value
| |
0.0002
|
0.0001
|
0.0004
|
< 0.0001
|
|
95% CI
| |
4.336 to 12.704
|
2.123 to 5.817
|
10.032 to 30.988
|
219.842 to 436.358
|
|
Risk stratification
|
|
LR
|
11 (33.3%)
|
12.76 ± 2.07
|
6.61 ± 1.54
|
18.72 ± 9.46
|
132.06 ± 91.49
|
|
HR
|
22 (66.7%)
|
19.3 ± 6.88
|
9.15 ± 3.08
|
35.73 ± 15.65
|
332.58 ± 207.02
|
|
P-value
| |
0.0045
|
0.0154
|
0.0024
|
0.0047
|
|
95% CI
| |
2.184 to 10.896
|
0.52 to 4.56
|
6.499 to 27.521
|
66.358 to 334.682
|
- LVSI, Lymphovascular space invasion, LNMs, Lymph nodes metastases, LR, Low Risk, HR, High Risk
